

***Request under Freedom of Information Act 2000***

Thank you for your request for information which we received on 08 November 2022.

I am pleased to confirm the following.

**In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:**

Abemaciclib monotherapy ~ 5

Aromatase inhibitor monotherapy (e.g., anastrozole, exemestane, letrozole) ~? Prescribed by GP

Tamoxifen monotherapy? Prescribed by GP

Abemaciclib + Tamoxifen 0

**In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:**

Abemaciclib + Aromatase inhibitor (e.g., anastrozole, exemestane, letrozole) ~ 14

Taxane and/or Anthracycline (monotherapy or in combination) ~?

Any other active systemic anti-cancer therapy

**How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

Anthracycline (e.g., doxorubicin or epirubicin) as a single agent

Atezolizumab +Nab-paclitaxel/Paclitaxel

Pembrolizumab

Sacituzumab Govitecan

Parp Inhibitors (Olaparib/Talazoparib) ~ 1

Eribulin as a single agent or in combination

Capecitabine as a single agent

Platinum (e.g., carboplatin or cisplatin) as a single agent

Taxane (e.g., docetaxel, paclitaxel, nab-paclitaxel) as a single agent

Taxane and/or Anthracycline in combination

We are unable to provide data on Triple Negative Breast Cancer (any stage) as our data does not differentiate between different stages

Any other active systemic anti-cancer therapy

=====

Any other active systemic anti-cancer therapy – for all stages

Epirubicin / Cyclophosphamide ~36

Docetaxel~ 28

Trastuzumab~ 23

Ribociclib ~24

Pertuzumab / Trastuzumab 26

Pembrolizumab~ 1

Palbociclib 15

Paclitaxel Albumin ~ 2

Paclitaxel 21

Gemcitabine~ 2

Zometa 18

Tucatinib~ 1

Vincristine 1

Trastuzumab Emtansine ~ 3

Trastuzumab Deruxtecan ~ 4

Atezolizumab +Nab-paclitaxel/Paclitaxel 1

Capecitabine as a single agent~12

Platinum (e.g., carboplatin or cisplatin) as a single agent 8 (Carboplatin)

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator

For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.